Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The daily Top 10 COVID papers

  Breast Cancer

  Free Subscription


2 Ann Oncol
1 Ann Surg Oncol
7 Anticancer Res
2 BMC Cancer
2 Breast Cancer (Auckl)
2 Breast Cancer Res
4 Breast J
3 Cancer
1 Cancer Epidemiol Biomarkers Prev
3 Clin Breast Cancer
1 Clin Cancer Res
3 Eur J Cancer
1 J Clin Oncol
2 J Natl Cancer Inst
1 Lancet
5 NPJ Breast Cancer
1 Oncogene
4 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Oncol

  1. FRANZOI MA, Romano E, Piccart M
    Immunotherapy for early breast cancer: too soon, too superficial, or just right?
    Ann Oncol. 2020 Dec 8. pii: S0923-7534(20)43198.
    PubMed         Abstract available

  2. GRINSHPUN A, Moss J, Uziely B
    Key Role for Liquid Biopsy in the Elimination of Breast Cancer Surgery following Neoadjuvant Therapy.
    Ann Oncol. 2020 Dec 7. pii: S0923-7534(20)43201.

    Ann Surg Oncol

  3. VAN LOEVEZIJN AA, van Duijnhoven FH, Vrancken Peeters MTFD
    ASO Author Reflections: The Pursuit of Eliminating Surgery after Neoadjuvant Systemic Therapy in Breast Cancer Patients.
    Ann Surg Oncol. 2020 Dec 10. pii: 10.1245/s10434-020-09324.

    Anticancer Res

  4. TSAI CL, Tsai CW, Chang WS, Su CH, et al
    Interleukin-13 Promoter Genotypes and Taiwanese Breast Cancer Susceptibility.
    Anticancer Res. 2020;40:6743-6749.
    PubMed         Abstract available

  5. ROBINSON AGJ, Kanaan YM, Copeland RL
    Combinatorial Cytotoxic Effects of 2,3-Dichloro-5,8-dimethoxy-1,4-naphthoquinone and 4-hydroxytamoxifen in Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2020;40:6623-6635.
    PubMed         Abstract available

  6. ANAYA-EUGENIO GD, Eggers NA, Ren Y, Rivera-ChAvez J, et al
    Apoptosis Induced by (+)-Betulin Through NF-kappaB Inhibition in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2020;40:6637-6647.
    PubMed         Abstract available

  7. NIWA Y, Asano M, Nakagawa T, France D, et al
    Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
    Anticancer Res. 2020;40:6699-6712.
    PubMed         Abstract available

  8. YAMADA A, Suzuki C, Shima H, Kida K, et al
    Aldehyde Dehydrogenase 1-related Genes in Triple-negative Breast Cancer Investigated Using Network Analysis.
    Anticancer Res. 2020;40:6733-6742.
    PubMed         Abstract available

  9. MACAIONE I, Galvano A, Graceffa G, Lupo S, et al
    Impact of BMI on Preoperative Axillary Ultrasound Assessment in Patients With Early Breast Cancer.
    Anticancer Res. 2020;40:7083-7088.
    PubMed         Abstract available

  10. VANNI G, Tazzioli G, Pellicciaro M, Materazzo M, et al
    Delay in Breast Cancer Treatments During the First COVID-19 Lockdown. A Multicentric Analysis of 432 Patients.
    Anticancer Res. 2020;40:7119-7125.
    PubMed         Abstract available

    BMC Cancer

  11. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
    BMC Cancer. 2020;20:1215.
    PubMed         Abstract available

  12. KIM JY, Jung EJ, Kim JM, Lee HS, et al
    Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis.
    BMC Cancer. 2020;20:1206.
    PubMed         Abstract available

    Breast Cancer (Auckl)

  13. QI J, Hu H, Yaghjyan L, An L, et al
    Association of Adipose Tissue Distribution With Type 2 Diabetes in Breast Cancer Patients.
    Breast Cancer (Auckl). 2020;14:1178223420972369.
    PubMed         Abstract available

  14. AL HAMAD M, Matalka I, Al Zoubi MS, Armogida I, et al
    Human Mammary Tumor Virus, Human Papilloma Virus, and Epstein-Barr Virus Infection Are Associated With Sporadic Breast Cancer Metastasis.
    Breast Cancer (Auckl). 2020;14:1178223420976388.
    PubMed         Abstract available

    Breast Cancer Res

  15. WATT GP, Sung J, Morris EA, Buys SS, et al
    Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study.
    Breast Cancer Res. 2020;22:138.
    PubMed         Abstract available

  16. SEREESONGSAENG N, McDowell SH, Burrows JF, Scott CJ, et al
    Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer.
    Breast Cancer Res. 2020;22:139.
    PubMed         Abstract available

    Breast J

  17. FALCO M, Masojc B, Kram A
    Locoregional relapse is a strong prognostic indicator of distant metastatic progression in breast cancer patients after negative sentinel lymph node biopsy.
    Breast J. 2020 Dec 2. doi: 10.1111/tbj.14118.
    PubMed         Abstract available

  18. MASOOD S
    Is it time to address the continuous dilemma of breast cancer disparities among African Americans? A call to action.
    Breast J. 2020 Dec 7. doi: 10.1111/tbj.14124.

  19. HELAL M, Mansour S, Khaled R, Bassam L, et al
    The role of automated breast ultrasound in the assessment of the local extent of breast cancer.
    Breast J. 2020 Dec 9. doi: 10.1111/tbj.14132.
    PubMed         Abstract available

  20. PABST L, Velten M, Fischbach C, Kalish M, et al
    Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer.
    Breast J. 2020 Dec 11. doi: 10.1111/tbj.14123.
    PubMed         Abstract available


  21. LEONE JP, Cole BF, Regan MM, Thurlimann B, et al
    Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial.
    Cancer. 2020 Dec 8. doi: 10.1002/cncr.33318.
    PubMed         Abstract available

  22. TAYLOR CE, Meisel JL
    Weighing the influence of race and obesity on outcomes in patients with early-stage breast cancer.
    Cancer. 2020 Dec 7. doi: 10.1002/cncr.33290.

  23. NYROP KA, Damone EM, Deal AM, Carey LA, et al
    Obesity, comorbidities, and treatment selection in Black and White women with early breast cancer.
    Cancer. 2020 Dec 7. doi: 10.1002/cncr.33288.
    PubMed         Abstract available

    Cancer Epidemiol Biomarkers Prev

  24. VON HOLLE A, O'Brien KM, Sandler DP, Janicek R, et al
    Association between serum iron biomarkers and breast cancer.
    Cancer Epidemiol Biomarkers Prev. 2020 Dec 8. pii: 1055-9965.EPI-20-0715.
    PubMed         Abstract available

    Clin Breast Cancer

  25. MURATA T, Watase C, Shiino S, Jimbo K, et al
    Development and Validation of a Preoperative Scoring System to Distinguish Between Nonadvanced and Advanced Axillary Lymph Node Metastasis in Patients With Early-stage Breast Cancer.
    Clin Breast Cancer. 2020 Nov 17. pii: S1526-8209(20)30292.
    PubMed         Abstract available

  26. KOZAR N, Kruusmaa K, Bitenc M, Argamasilla R, et al
    Identification of Novel Diagnostic Biomarkers in Breast Cancer Using Targeted Metabolomic Profiling.
    Clin Breast Cancer. 2020 Nov 11. pii: S1526-8209(20)30232.
    PubMed         Abstract available

  27. YANG W, He X, He C, Peng L, et al
    Impact of ESR1 Polymorphisms on Risk of Breast Cancer in the Chinese Han Population.
    Clin Breast Cancer. 2020 Oct 16. pii: S1526-8209(20)30262.
    PubMed         Abstract available

    Clin Cancer Res

  28. GARRIDO-CASTRO AC, Spurr LF, Hughes ME, Li YY, et al
    Genomic characterization of de novo metastatic breast cancer.
    Clin Cancer Res. 2020 Dec 8. pii: 1078-0432.CCR-20-1720.
    PubMed         Abstract available

    Eur J Cancer

  29. KOIVULUOMA S, Tervasmaki A, Kauppila S, Winqvist R, et al
    Exome sequencing identifies a recurrent variant in SERPINA3 associating with hereditary susceptibility to breast cancer.
    Eur J Cancer. 2020;143:46-51.
    PubMed         Abstract available

  30. GERRATANA L, Davis AA, Polano M, Zhang Q, et al
    Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.
    Eur J Cancer. 2020;143:147-157.
    PubMed         Abstract available

  31. PFOB A, Sidey-Gibbons C, Lee HB, Tasoulis MK, et al
    Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy.
    Eur J Cancer. 2020;143:134-146.
    PubMed         Abstract available

    J Clin Oncol

  32. SPARANO JA, Crager MR, Tang G, Gray RJ, et al
    Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer.
    J Clin Oncol. 2020 Dec 11:JCO2003007. doi: 10.1200/JCO.20.03007.
    PubMed         Abstract available

    J Natl Cancer Inst

  33. MACINNIS RJ, Knight JA, Chung WK, Milne RL, et al
    Comparing Five-Year and Lifetime Risks of Breast Cancer in the Prospective Family Study Cohort.
    J Natl Cancer Inst. 2020 Dec 10. pii: 6029579. doi: 10.1093.
    PubMed         Abstract available

  34. ETZIONI R, Shen Y, Shih YT
    Identifying Preferred Breast Cancer Risk Predictors: A Holistic Perspective.
    J Natl Cancer Inst. 2020 Dec 10. pii: 6029577. doi: 10.1093.


  35. PARSONS HA, Burstein HJ
    Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations.
    JAMA. 2020 Dec 10. pii: 2774294. doi: 10.1001/jama.2020.23371.

  36. WANG X, Wang SS, Huang H, Cai L, et al
    Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Cli
    JAMA. 2020 Dec 10. pii: 2774295. doi: 10.1001/jama.2020.23370.
    PubMed         Abstract available


  37. CORTES J, Cescon DW, Rugo HS, Nowecki Z, et al
    Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Lancet. 2020;396:1817-1828.
    PubMed         Abstract available

    NPJ Breast Cancer

  38. LI W, Newitt DC, Gibbs J, Wilmes LJ, et al
    Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.
    NPJ Breast Cancer. 2020;6:63.
    PubMed         Abstract available

  39. GIARDIELLO D, Kramer I, Hooning MJ, Hauptmann M, et al
    Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer.
    NPJ Breast Cancer. 2020;6:60.
    PubMed         Abstract available

  40. JINDAL S, Pennock ND, Klug A, Narasimhan J, et al
    S-nitrosylated and non-nitrosylated COX2 have differential expression and distinct subcellular localization in normal and breast cancer tissue.
    NPJ Breast Cancer. 2020;6:62.
    PubMed         Abstract available

  41. YI Z, Rong G, Guan Y, Li J, et al
    Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer.
    NPJ Breast Cancer. 2020;6:59.
    PubMed         Abstract available

  42. XI PW, Zhang X, Zhu L, Dai XY, et al
    Oncogenic action of the exosome cofactor RBM7 by stabilization of CDK1 mRNA in breast cancer.
    NPJ Breast Cancer. 2020;6:58.
    PubMed         Abstract available


  43. KONG D, Zhou H, Neelakantan D, Hughes CJ, et al
    VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk.
    Oncogene. 2020 Dec 9. pii: 10.1038/s41388-020-01539.
    PubMed         Abstract available

    PLoS One

  44. SHI Y, Gong W, Gong X, Wang P, et al
    Genome-wide DNA methylation analysis of breast cancer MCF-7 / Taxol cells with MeDIP-Seq.
    PLoS One. 2020;15:e0241515.
    PubMed         Abstract available

  45. MAO Y, Zhao Y, Zhang Y, Yang H, et al
    In-depth characterization and comparison of the N-glycosylated proteome of two-dimensional- and three-dimensional-cultured breast cancer cells and xenografted tumors.
    PLoS One. 2020;15:e0243789.
    PubMed         Abstract available

  46. NAGHIBI L, Yazdani M, Momtazi-Borojeni AA, Razazan A, et al
    Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer.
    PLoS One. 2020;15:e0243550.
    PubMed         Abstract available

  47. DE LA CRUZ-KU G, Chambergo-Michilot D, Torres-Roman JS, Rebaza P, et al
    Neutrophil-to-lymphocyte ratio predicts early mortality in females with metastatic triple-negative breast cancer.
    PLoS One. 2020;15:e0243447.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.